| Market Capitalization (Millions $) |
272 |
| Shares
Outstanding (Millions) |
111 |
| Employees |
103 |
| Revenues (TTM) (Millions $) |
18 |
| Net Income (TTM) (Millions $) |
-125 |
| Cash Flow (TTM) (Millions $) |
39 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Alector Inc.
is a clinical-stage biotechnology company focused on the development of immunotherapy treatments for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and various forms of dementia.
The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector's approach to treating neurodegenerative diseases is based on the principles of immunology and genetics.
The company develops drugs that target the immune system, specifically the immune cells in the brain, to help clear toxic proteins that are linked to neurodegeneration.
These drugs are designed to activate the body's own immune system to fight disease and promote healing.
The company's pipeline includes a number of potential treatments for Alzheimer's disease, including AL001, a drug designed to target the progranulin pathway, and AL002, which targets a specific form of Tau protein.
Alector is also developing drugs for Parkinson's disease and frontotemporal dementia.
Alector has formed partnerships with several pharmaceutical companies to accelerate the development of its drugs, including AbbVie, GlaxoSmithKline, and Eli Lilly.
The company has also raised significant funding, including $133 million in an initial public offering in 2019.
Overall, Alector is focused on developing new treatments for debilitating and currently untreatable neurological conditions, with the potential to improve the lives of millions of people worldwide.
Company Address: 131 Oyster Point Blvd South San Francisco 94080 CA
Company Phone Number: 231-5660 Stock Exchange / Ticker: NASDAQ ALEC
|
1.11%